South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, progress in drug and vaccine development, lessons learned and the preparations being made to return to everyday life.
While South Korea has recently eased social distancing restrictions as the coronavirus situation in the country has improved in recent weeks, new cases linked to clubs in Seoul's Itaewon district are a reminder of how easy it is for the infectious disease to spread rapidly again.
The country has generally been praised for its early detection, tracking and contact tracing efforts and largely successful control measures. The Korea Centers for Disease Control & Prevention (KCDC) and...
Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.
Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.
Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.
